Intended Result		Your Report	Your Score
Specimen 8260	Rubella IgG status not designated	Rubella IgG positive (>=10 IU/mL)	Not scored
Specimen 8261	Rubella IgG status not designated	Rubella IgG negative (<10 IU/mL)	Not scored
Specimen 8262	Rubella IgG positive (>=10 IU/mL)	Rubella IgG positive (>=10 IU/mL)	2
Specimen 8263	Rubella IgG negative (<10 IU/mL)	Rubella IgG negative (<10 IU/mL)	2
Specimen 8264	Rubella IgG positive (>=10 IU/mL)	Rubella IgG positive (>=10 IU/mL)	2
Specimen 8265	Rubella IgG status not designated	Rubella IgG positive (>=10 IU/mL)	Not scored

Cumulative score information
Total number of specimens sent to you for **UK NEQAS for Rubella IgG serology** over the last 2 distributions is 12
For these distributions specimen numbers 7964 7965 7966 7968 8262 8263 8264 have been analysed and scored.
Number of reports scored 7
Number of specimens reported as not examined (not scored) 0
Number of specimens received too late for analysis (not scored) 0
Number of specimens for which no report was received (not scored) 0
Your cumulative score for these specimens was 14 out of a possible total of 14
The mean score calculated from the reports returned by **UK** laboratories was 13.92 with a standard error of 0.98.

Performance rating
Your performance rating for **UK NEQAS for Rubella IgG serology** (i.e. the number of standard errors by which your cumulative score lies above or below the mean) for UK laboratories is 0.08.
A performance rating of more than 1.96 standard errors below the mean indicates possible poor performance.
Your performance rating may change if other participants' results are amended.
No score penalty is incurred for non return of reports. However non return of results may be used as a measure of poor performance.





Comments: Overall performance was outstanding with 99.6% of participants reporting the intended results for scored specimens.

Specimen 8260: 94 participants (60.3%) reported this specimen as Rubella IgG positive and 62 participants (39.7%) reported this specimen as Rubella IgG negative with an overall method median of 12 IU/ml. Refer to the comments pages 4-6 for more details.
Specimen 8261: 22 participants (14.1%) reported this specimen as Rubella IgG positive and 134 participants (85.9%) reported this specimen as Rubella IgG negative with an overall method median of 7 IU/ml. Refer to the comments pages 4-6 for more details.
Specimen 8262: 155 participants (99.4%) reported this specimen as Rubella IgG positive, with an overall method median of 23 IU/ml. One participant (0.6%) reported a Rubella IgG negative result for this specimen.
Specimen 8263: all participants returning results (100%) reported this specimen as Rubella IgG negative, with an overall method median of 0 IU/ml.
Specimen 8264: 155 participants (99.4%) reported this specimen as Rubella IgG positive, with an overall method median of 46 IU/ml. One participant (0.6%) reported a Rubella IgG negative result for this specimen.
Specimen 8265: 101 participants (64.7%) reported this specimen as Rubella IgG positive and 55 participants (35.3%) reported this specimen as Rubella IgG negative with an overall method median of 16 IU/ml. Refer to the comments pages 4-6 for more details.

Turn around time: The time taken to report your results was 0-days. This information is provided for your own use and does not form part of your performance assessment.

Acknowledgements: We thank colleagues at UKHSA Manchester, UKHSA Birmingham, UKHSA Virus Reference Division in Colindale and NIBSC for their assistance with pre-distribution testing.

Enquiries: Pre-distribution test results are available should you experience a technical failure and wish to discuss the results. Written enquiries about this distribution should be addressed to Dr Sanjiv Rughooputh at organiser@ukneqasmicro.org.uk. For repeat specimens in case of an EQA failure investigation, please request using the web form at **https://ukneqasmicro.org.uk/participant-info/order-repeat-specimens.**

Report authorised by: Dr Sanjiv Rughooputh, Scheme Organiser.

Operated by UK Health Security Agency
National Infection Service
61 Colindale Avenue
Colindale
London NW9 5EQ

© Copyright. The data in UK NEQAS reports are confidential. Participants must consult the scheme organiser before quoting data from the scheme.
UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 11:04 on Wednesday 27 March 2024

Six specimens were dispatched with a request for screening of Rubella IgG. All specimens were derived from neat thrombinised human plasma (serum) donations. Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8260 — Rubella IgG status not designated

	n (UK)	range	median	5%-95%
All methods	168 (85)	2-49	12	8-46
Abbott : Architect	28 (16)	7-10	9	8-9
Abbott: Alinity	30 (6)	7-10	8	8-9
Beckman : Access	6 (6)	13-15	14	13-15
bioMerieux : Vidas	14 (10)	10-16	13	10-15
DiaSorin : Liaison	26 (8)	8-20	12	10-17
Euroimmun	2 (2)	10-15		
Other	3 (1)	12-20	12	12-19
Roche	26 (17)	38-49	43	39-49
Roche : Elecsys	5 (3)	9-46	41	15-45
Siemens:ADVIA Centaur	6 (6)	6-22	12	6-20
Siemens:Atellica IM	6 (3)	13-30	19	13-30
Vircell	4	2-23	12	4-22



Quantitative report :
Your result : 15 IU/mL
Your method median : 12.5 IU/mL

Qualitative report :
Your Report :
Rubella IgG positive (>=10 IU/mL)

Your Score : Not scored

Overall Results	UK	All	Score
Rubella IgG positive	46	94	NS
Rubella IgG negative	24	62	NS
Total	70	156	
% Correct			

Specimen : 8261 — Rubella IgG status not designated

	n (UK)	range	median	5%-95%
All methods	167 (84)	1-17	7	3-12
Abbott : Architect	28 (16)	3-4	4	3-4
Abbott: Alinity	30 (6)	3-4	4	3-4
Beckman : Access	6 (6)	10-13	12	10-13
bioMerieux : Vidas	14 (10)	6-9	8	7-9
DiaSorin : Liaison	26 (8)	5-8	7	5-8
Euroimmun	2 (2)	6-10		
Other	3 (1)	7-17	10	7-16
Roche	26 (17)	7-10	8	7-9
Roche : Elecsys	5 (3)	8-8	8	8-8
Siemens:ADVIA Centaur	6 (6)	8-13	9	8-12
Siemens:Atellica IM	6 (3)	11-16	12	11-16
Vircell	4	1-13	8	2-12



Quantitative report :
Your result : 10 IU/mL
Your method median : 8.0 IU/mL

Qualitative report :
Your Report :
Rubella IgG negative (<10 IU/mL)

Your Score : Not scored

Overall Results	UK	All	Score
Rubella IgG positive	12	22	NS
Rubella IgG negative	58	134	NS
Total	70	156	
% Correct			

Specimen : 8262 — Rubella IgG positive (>=10 IU/mL)

	n (UK)	range	median	5%-95%
All methods	169 (86)	3-107	23	13-94
Abbott : Architect	28 (16)	12-15	14	12-15
Abbott: Alinity	30 (6)	12-16	14	12-15
Beckman : Access	6 (6)	26-29	27	26-28
bioMerieux : Vidas	14 (10)	17-27	23	18-26
DiaSorin : Liaison	26 (8)	21-30	25	21-28
Euroimmun	2 (2)	27-28		
Other	3 (1)	21-26	23	21-26
Roche	26 (17)	61-99	84	69-98
Roche : Elecsys	5 (3)	68-94	86	71-93
Siemens:ADVIA Centaur	6 (6)	21-107	82	21-104
Siemens:Atellica IM	6 (3)	19-104	20	19-83
Vircell	4	3-51	29	6-48



Quantitative report :
Your result : 28 IU/mL
Your method median : 27.5 IU/mL

Qualitative report :
Your Report :
Rubella IgG positive (>=10 IU/mL)

Your Score : 2

Overall Results	UK	All	Score
Rubella IgG positive	69	155	2
Rubella IgG negative	1	1	-1
Total	70	156	
% Correct	98.6	99.4	

Operated by UK Health Security Agency
National Infection Service
61 Colindale Avenue
Colindale
London NW9 5EQ

© Copyright. The data in UK NEQAS reports are confidential. Participants must consult the scheme organiser before quoting data from the scheme.

UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 11:04 on Wednesday 27 March 2024

Six specimens were dispatched with a request for screening of Rubella IgG. All specimens were derived from neat thrombinised human plasma (serum) donations. Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8263 Rubella IgG negative (<10 IU/mL)

	n (UK)	range	median	5%-95%
All methods	149 (72)	0-7	0	0-2
Abbott : Architect	28 (16)	0-0	0	0-0
Abbott: Alinity	30 (6)	0-0	0	0-0
Beckman : Access	6 (6)	0-1	0	0-1
bioMerieux : Vidas	14 (10)	0-1	1	0-1
DiaSorin : Liaison	26 (8)	1-3	2	2-2
Euroimmun	1 (1)	1-1		
Other	2	1-2		
Roche	17 (11)	0-0	0	0-0
Roche : Elecsys	3 (2)	0-0	0	0-0
Siemens:ADVIA Centaur	3 (3)	0-1	0	0-1
Siemens:Atellica IM	5 (3)	0-7	1	0-7
Vircell	4	0-7	4	0-7

Number of reports for non-numeric or off-scale results

Rubella IgG IU/mL	Your method	All methods
<5	1	17
<10	0	3

Quantitative report :
Your result : <5 IU/mL
Your method median : 1.0 IU/mL

Qualitative report :
Your Report :
Rubella IgG negative (<10 IU/mL)
Your Score : 2

Overall Results	UK	All	Score
Rubella IgG positive	0	0	-1
Rubella IgG negative	69	155	2
Total	69	155	
% Correct	100	100	

Specimen : 8264 Rubella IgG positive (>=10 IU/mL)

	n (UK)	range	median	5%-95%
All methods	168 (85)	4-178	46	26-160
Abbott : Architect	28 (16)	25-31	28	25-31
Abbott: Alinity	30 (6)	23-32	28	26-31
Beckman : Access	6 (6)	48-59	52	48-58
bioMerieux : Vidas	13 (9)	47-62	51	47-62
DiaSorin : Liaison	26 (8)	36-51	46	38-51
Euroimmun	2 (2)	47-47		
Other	3 (1)	42-50	47	42-50
Roche	26 (17)	122-178	148	127-176
Roche : Elecsys	5 (3)	122-170	151	128-167
Siemens:ADVIA Centaur	6 (6)	39-136	86	43-127
Siemens:Atellica IM	6 (3)	36-112	40	36-94
Vircell	4	4-79	54	11-76



Quantitative report :
Your result : 47 IU/mL
Your method median : 47.0 IU/mL

Qualitative report :
Your Report :
Rubella IgG positive (>=10 IU/mL)
Your Score : 2

Overall Results	UK	All	Score
Rubella IgG positive	70	155	2
Rubella IgG negative	0	1	-1
Total	70	156	
% Correct	100	99.4	

Specimen : 8265 Rubella IgG status not designated

	n (UK)	range	median	5%-95%
All methods	154 (77)	2-619	16	8-500
Abbott : Architect	28 (16)	6-9	8	7-9
Abbott: Alinity	30 (6)	7-9	8	7-9
Beckman : Access	6 (6)	26-30	28	26-30
bioMerieux : Vidas	14 (10)	11-17	14	11-16
DiaSorin : Liaison	26 (8)	16-23	21	17-23
Euroimmun	2 (2)	14-18		
Other	3 (1)	21-27	26	22-27
Roche	16 (10)	431-619	498	447-530
Roche : Elecsys	3 (2)	473-500	500	476-500
Siemens:ADVIA Centaur	6 (6)	14-98	82	16-98
Siemens:Atellica IM	6 (3)	22-120	24	22-96
Vircell	4	2-28	16	4-26



Quantitative report :
Your result : 18 IU/mL
Your method median : 16.0 IU/mL

Qualitative report :
Your Report :
Rubella IgG positive (>=10 IU/mL)
Your Score : Not scored

Overall Results	UK	All	Score
Rubella IgG positive	50	101	NS
Rubella IgG negative	20	55	NS
Total	70	156	
% Correct			

Operated by UK Health Security Agency
National Infection Service
61 Colindale Avenue
Colindale
London NW9 5EQ

© Copyright. The data in UK NEQAS reports are confidential. Participants must consult the scheme organiser before quoting data from the scheme.

UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 11:04 on Wednesday 27 March 2024

Comments on distribution 5519

One hundred and sixty five (165) sets of specimens were dispatched and 156 participants returned their results within the specified time; representing a participation rate of 94.5%. Compared to previous distribution 5425, where the return rate was 98.2%., this is a decrease of 3.7%.

Overall, performance in this distribution was outstanding with 99.6% of participants reporting the intended results for the scored specimen. Compared to previous distribution 5425, where the overall performance was 99.5%, this is an increase of 0.1%.

Specimens included in this distribution were derived from single thrombinised human plasma (serum) donations and tested prior to dispatch by 5 different EIA methods: Single Radial Haemolysis (SRH), Virion Serion, Roche cobas, Euroimmun EIA for Rubella IgG and Abbott Alinity.

The presence of Rubella IgG was confirmed by Euroimmun Rubella avidity kit as illustrated in Table 1.

Specimen Number	SRH	Virion Serion		Roche cobas	Euroimmun EIA	Euroimmun Rubella Avidity	Abbott Alinity
	IU/mL	IU/mL	OD	IU/mL	IU/mL	% AI	IU/mL
8260	5 (negative)	7.6 (negative)	0.405	44.3 (positive)	14.9 (positive)	48.7 (equivocal)	6.04 (negative)
8261	4.8 (negative)	6.9 (negative)	0.332	12.4 (positive)	9.5 (equivocal)	67.3 (high avidity)	3.56 (negative)
8265	4.5 (negative)	10.7 (equivocal)	0.531	500 (positive)	18.1 (positive)	63.3 (high avidity)	7.97 (negative)
Cut-off	10	10	NA	10	10	>60 (high avidity)	10

Table 1: Pre-distribution test results for specimens 8260,8261 and 8265 in distribution 5519

The quantification results for the positive specimens however, varied between methods. Any value less than 10 is considered as negative as per our scoring policy:
“Scoring is based on the participants' ability to determine the presence (Positive - greater than or equal to 10 IU/mL) or absence (Negative- less than 10 IU/mL) of Rubella IgG in each serum specimen”.

© Copyright. The data in UK NEQAS reports are confidential. Participants must consult the scheme organiser before quoting data from the scheme.
UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 11:04 on Wednesday 27 March 2024

Specimen 8260 Rubella IgG status not designated: not scored

The original material to make this specimen had tested positive on Abbott Axsym with a concentration of 13.4 IU/mL.

In pre-distribution testing, the specimen tested negative (5 IU/mL) by SRH, Virion Serion (7.6 IU/mL) and Abbott Alinity (6.04 IU/mL). It tested positive with a concentration of 44.3 IU/mL with Roche cobas and 14.9 IU/mL) with Euroimmun Rubella IgG EIA. But gave an equivocal avidity of 48.7% with the Euroimmun Rubella Avidity assay as illustrated in Table 1.

Of the 156 participants who returned results for this distribution, 60.3% (94) reported a Rubella IgG positive result (> 10 IU/mL) and 39.7% (94) reported a negative result.

Due to discrepant pre-distribution testing results, this specimen has not been scored.

Specimen 8261 Rubella IgG status not designated: not scored

The original material to make this specimen had tested negative on Abbott Axsym with a concentration of 7.8 IU/mL.

In pre-distribution testing, this specimen tested negative (4.8IU/mL) by SRH, Virion Serion (6.9 IU/mL) and Abbott Alinity (3.56 IU/mL). It tested positive at a concentration of 12.4 IU/mL with Roche cobas, but equivocal (9.5 IU/mL) with Euroimmun Rubella IgG EIA and gave a high avidity of 67.3% with the Euroimmun Rubella Avidity assay as illustrated in Table 1.

Of the 156 participants who returned results for this distribution, 85.9% (134) reported a Rubella IgG negative result (<10 IU/mL) and 14.1% (22) reported a positive result.

Due to discrepant pre-distribution testing results, this specimen has not been scored.

Specimen 8265 Rubella IgG status not designated: not scored

The original material to make this specimen had tested positive by SRH with a concentration of 24 IU/mL.

In pre-distribution testing, the specimen tested negative (4.5 IU/mL) by SRH and Abbott Alinity (7.97 IU/mL), equivocal by Virion Serion (10.7 IU/mL). It tested positive with a concentration of 500 IU/mL with Roche cobas and 18.1 IU/mL) with Euroimmun Rubella IgG EIA. and gave a high avidity of 63.3% with the Euroimmun Rubella Avidity assay as illustrated in Table 1.

Of the 156 participants who returned results for this distribution, 64.7% (101) reported a Rubella IgG positive result (> 10 IU/mL) and 35.3% (55) reported a negative result.

Due to discrepant pre-distribution testing results, this specimen has not been scored.

© Copyright. The data in UK NEQAS reports are confidential. Participants must consult the scheme organiser before quoting data from the scheme.

Participants who did not obtain the intended results are requested to investigate and report the plausible root cause by completing an incident review form (IRF) online within 30 days of this report being published.

Non return of results without a valid reason is considered as poor performance and should also be reported in a similar manner.

IRFs are taken into considerations when poor performance analysis is carried out for the National Quality Assurance Advisory Panel (NQAAP). IRFs can be completed on the following link: https://uknegasmicro.org.uk/incident-review-form/

End of report

Operated by UK Health Security Agency
National Infection Service
61 Colindale Avenue
Colindale
London NW9 5EQ

© Copyright. The data in UK NEQAS reports are confidential. Participants must consult the scheme organiser before quoting data from the scheme.

UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 11:04 on Wednesday 27 March 2024